SCHEMBL13485435

SCHEMBL13485435

COc1cc2ncnc(Nc3c(CN(CCCCCCl)C(=O)OCc4ccccc4)ccc4c3OCO4)c2cc1OC(C)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 12/20 0.46
▸ SRC P12931 10/20 0.46
▸ CSK P41240 3/20 0.45
▸ TEK Q02763 3/20 0.45
▸ EPHB4 P54760 1/20 0.45
▸ EGFR P00533 6/20 0.42
▸ FYN P06241 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ PDE5A O76074 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HDAC3 O15379 4/20 0.38
▸ HDAC4 P56524 4/20 0.38
▸ HDAC1 Q13547 4/20 0.38
▸ HDAC7 Q8WUI4 4/20 0.38
▸ HDAC2 Q92769 4/20 0.38
▸ HDAC10 Q969S8 4/20 0.38
▸ HDAC11 Q96DB2 4/20 0.38
▸ HDAC8 Q9BY41 4/20 0.38
▸ HDAC6 Q9UBN7 4/20 0.38
▸ HDAC9 Q9UKV0 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13485434 0.95 SRC (0.44) KDRSRCCSKTEKEPHB4
SCHEMBL13485436 0.92 SRC (0.43) KDRSRCCSKTEKEPHB4
SCHEMBL13485492 0.91 EGFR (0.41) KDRSRCCSKTEKEPHB4
SCHEMBL13485511 0.87 EGFR (0.38) KDRSRCCSKTEKEPHB4
SCHEMBL13485489 0.86 EGFR (0.41) KDRSRCCSKTEKEPHB4
SCHEMBL13485493 0.83 EGFR (0.42) KDRSRCEGFRHDAC3HDAC4
SCHEMBL13485444 0.79 SRC (0.51) KDRSRCCSKTEKEPHB4
SCHEMBL13485512 0.78 EGFR (0.39) KDRSRCEGFRFYNERBB2
SCHEMBL13485464 0.78 SRC (0.49) KDRSRCCSKTEKEPHB4
SCHEMBL6583527 0.74 KDR (0.74) KDRSRCCSKTEKEPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044084-B1 MTKI QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2016-02-17 — — EP disclosed
US-8492377-B2 MTKI quinazoline derivatives JANSSEN PHARMACEUTICA NV (BE) 2013-07-23 — — US disclosed
US-8492377-B2 MTKI quinazoline derivatives JANSSEN PHARMACEUTICA NV (BE) 2013-07-23 — — US disclosed
US-20100029627-A1 MTKI QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2010-02-04 — — US disclosed
US-20100029627-A1 MTKI QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2010-02-04 — — US disclosed
WO-2008006884-A2 MTKI QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029627-A1 MTKI QUINAZOLINE DERIVATIVES NR4A3, NR4A1, NR5A2 KDR 1987/4885SRC 1853/4885CSK 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback